Stomach Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Stomach Cancer Market Outlook
Thelansis’s “Stomach Cancer Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Stomach Cancer treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Stomach Cancer Overview
Stomach
cancer, also known as gastric cancer, is a malignancy that originates from the
stomach lining. It is slow-growing cancer and is considered a multifactorial
disease. The International Agency for Research on Cancer (IARC) has classified
the bacterium Helicobacter pylori (H. pylori) as a carcinogen in humans due to
the evidence linking H. pylori infection and an increased risk of gastric
cancer. The mechanism by which H. pylori acts as a carcinogen is believed to be
indirect, through the induction of gastritis, which can lead to the development
of precancerous conditions such as gastric atrophy, metaplasia, and dysplasia.
Individuals with certain genetic disorders, such as hereditary diffuse gastric
cancer, Peutz-Jeghers syndrome, and familial adenomatous polyposis, have an
increased risk of developing stomach cancer. Mutations or deletions in genes
such as p53, BRCA2, MSH2, and MLH1 also increase the risk of gastric cancer.
The symptoms of stomach cancer can be classified into two stages: early stage
and advanced stage. The most common type of stomach cancer is adenocarcinoma,
which accounts for approximately 90% of all cases. Other types of stomach
cancer include gastric lymphomas, gastrointestinal stromal tumors, and
carcinoid tumors. The risk factors for developing stomach cancer include age,
gender, H. pylori infection, family history/genetics, race/ethnicity, diet,
previous surgery or health conditions, occupational exposure, tobacco and
alcohol use, and obesity. The five-year survival rate for individuals diagnosed
with stomach cancer is 31.2%.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment